Associated Papers
Impact of insertion/deletion mutations affecting the ABL1 gene in Ph-positive leukemias.
Lucini C et al.
Haematologica, 2026
Structural insights into WRN helicase reveal conformational states and opportunities for MSI-H cancer drug discovery.
Fletcher CT et al.
Communications Biology, 2026
Next-generation sequencing from chronic myeloid leukemia dried blood spots: insights and implications for global oncology.
Oehler VG et al.
Leukemia, 2026
The silent players: Atypical BCR‑ABL isoforms as biomarkers and therapeutic hurdles in CML pathogenesis (Review).
Zhou X et al.
Oncology Reports, 2025
MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.
Dyagil IS et al.
Problemy Radiatsiinoi Medytsyny Ta Radiobiolohii, 2025
Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation.
Pierro F et al.
International Journal of Molecular Sciences, 2025
Characterizing Variants of Uncertain Drug Resistance (VUDRs) Using Quantitative Measurements at Clinical Exposures.
Inam H et al.
Biorxiv : the Preprint Server for Biology, 2025
Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.
Takahashi N et al.
International Journal of Hematology, 2025
Decoding genomic rearrangements for cancer driver discovery.
Seo E et al.
Molecules and Cells, 2025
Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.
Newman H et al.
Hemasphere, 2025
Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies.
Brlek P et al.
Cancers, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8+ T cell immunity in TNBC.
Liang Y et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy, 2025
Microfluidic single-cell drug screening: toward personalized precision therapy in chronic myeloid leukemia.
Jeon H et al.
Lab on a Chip, 2025
Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.
Jung Y et al.
Nature Biomedical Engineering, 2025
Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia.
Lo Schiavo F et al.
Molecular Cancer, 2025
How will genomic testing impact a clinician's choice for managing chronic myeloid leukemia?
Sia J et al.
Expert Review of Hematology, 2025
Computational Tools to Analyze the Pathogenicity and Drug Sensitivity of Oncogenic Mutants.
Mullaguri SC et al.
Current Protocols, 2025
Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia.
Aptullahoglu E et al.
International Journal of Molecular Sciences, 2025
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
Lan Y et al.
British Journal of Cancer, 2025
Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report.
Zhou X et al.
Oncology Letters, 2025
Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yang C et al.
Leukemia, 2025
Hemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases.
Won W et al.
Signal Transduction and Targeted Therapy, 2025
On-target toxicity limits the efficacy of CDK11 inhibition against cancers with 1p36 deletions.
Julian L et al.
Biorxiv : the Preprint Server for Biology, 2025
Synergistic effect of asciminib with reduced doses of ponatinib in human Ph + myeloid leukemia with the T315M mutation.
Nguyen T et al.
International Journal of Hematology, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.
Pagliarini RA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Dr. Kinase: predicting the drug-resistance hotspots of protein kinases.
Lin S et al.
Nucleic Acids Research, 2025
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
Krizkova J et al.
Leukemia, 2025
Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.
Lewandowski K et al.
Annals of Hematology, 2025
Structural Identification of Major Molecular Determinants for Phosphotyrosine Recognition in Tyrosine Kinases Reveals Tumour Promoting and Suppressive Functions.
Cheng N et al.
Biorxiv : the Preprint Server for Biology, 2025
A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation Sequencing Assays.
Galbo PM et al.
The Journal of Molecular Diagnostics : Jmd, 2025
Rare Atypical Ela3 BCR-ABL transcript in acute Lymphoblastic Leukemia: a case report.
Xu L et al.
African Health Sciences, 2025
From Sanger to Oxford Nanopore MinION Technology: The Impact of Third-Generation Sequencing on Genetic Hematological Diagnosis.
Larráyoz MJ et al.
Cancers, 2025
Dual Disruption of DNA Repair by a Novel CHK2 Inhibitor, ART-446, and Olaparib is a Promising Strategy for Triple-Negative Breast Cancer Therapy.
Kang HJ et al.
Biomolecules & Therapeutics, 2025
Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients.
Dhangar S et al.
Leukemia Research, 2025
Allele-Specific PCR for Detection of Missense Mutations in the Chimeric BCR::ABL1 Gene Causing Failure of Tyrosine Kinase Inhibitor Therapy in CML Patients.
Skripkina A et al.
International Journal of Molecular Sciences, 2025
Current and future of targeted therapies against BCR::ABL kinases.
Jayavel S et al.
Journal of the Egyptian National Cancer Institute, 2025
Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion.
Shi S et al.
Leukemia Research, 2025
Utility of the Base Editing System for Introducing Drug-Resistant Gene Mutations Into Human Leukemia Cellular Models.
Nguyen T et al.
Cureus, 2025
Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia: A Report From the RESIDIAG Study.
Guerineau H et al.
American Journal of Hematology, 2025
Multiplexed in vivo base editing identifies functional gene-variant-context interactions.
Acosta J et al.
Biorxiv : the Preprint Server for Biology, 2025
Image-Based Phenotypic Profiling Enables Rapid and Accurate Assessment of EGFR-Activating Mutations in Tissues from Lung Cancer Patients.
Lei Q et al.
Journal of the American Chemical Society, 2025
A CML Patient Carrying BCR::ABL1 Splicing Variants Did Not Experience Blast Crisis for 15 Years without Responding to Various TKIs.
Nakamura F et al.
Internal Medicine (tokyo, Japan), 2025
Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.
Cullot G et al.
Annals of Hematology, 2025
Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia.
Fontecha MB et al.
Leukemia Research, 2025
Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome.
Baldwin AG et al.
Journal of Medicinal Chemistry, 2025
Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation.
Quezada Meza CP et al.
International Journal of Biological Macromolecules, 2025
Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population.
Chaudhary P et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2025
Error-corrected ultradeep next-generation sequencing for detection of clonal haematopoiesis and haematological neoplasms - sensitivity, specificity and accuracy.
Tursky ML et al.
Plos One, 2025